OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $378,562 | +55.3% | 120,561 | +155.2% | 0.00% | – |
| Q2 2023 | $243,743 | -5.7% | 47,237 | -3.7% | 0.00% | – |
| Q1 2023 | $258,530 | +139.2% | 49,057 | +27.5% | 0.00% | – |
| Q4 2022 | $108,101 | -54.6% | 38,470 | -33.0% | 0.00% | – |
| Q3 2022 | $238,000 | +14.4% | 57,425 | +11.1% | 0.00% | – |
| Q2 2022 | $208,000 | -22.4% | 51,677 | -4.5% | 0.00% | – |
| Q1 2022 | $268,000 | -28.5% | 54,099 | +0.5% | 0.00% | – |
| Q4 2021 | $375,000 | -60.0% | 53,853 | -42.6% | 0.00% | -100.0% |
| Q3 2021 | $938,000 | +3.4% | 93,751 | +46.6% | 0.00% | 0.0% |
| Q2 2021 | $907,000 | -7.4% | 63,933 | +7.2% | 0.00% | 0.0% |
| Q1 2021 | $979,000 | -18.6% | 59,654 | +2.8% | 0.00% | 0.0% |
| Q4 2020 | $1,202,000 | +69.1% | 58,044 | -37.8% | 0.00% | 0.0% |
| Q3 2020 | $711,000 | -5.7% | 93,385 | +3.2% | 0.00% | 0.0% |
| Q2 2020 | $754,000 | +139.4% | 90,530 | +42.2% | 0.00% | 0.0% |
| Q1 2020 | $315,000 | – | 63,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |